Haoxi Health Technology Launches $80 Million At-the-Market Share Offering Program

An update from Haoxi Health Technology Limited Class A ( (HAO) ) is now available.

On January 23, 2026, Haoxi Health Technology Limited entered into a sales agreement with Aegis Capital Corp. to establish an at-the-market equity offering program for up to $80 million of its Class A ordinary shares. The shares will be issued from time to time under an effective shelf registration on Form F-3, with Aegis acting as sales agent on a commission of 2.5% of gross proceeds and being reimbursed for certain expenses; the arrangement gives Haoxi a flexible mechanism to raise additional capital as needed, which could support its growth plans but may also dilute existing shareholders depending on the scale and timing of issuances.

The most recent analyst rating on (HAO) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Haoxi Health Technology Limited Class A stock, see the HAO Stock Forecast page.

Spark’s Take on HAO Stock

According to Spark, TipRanks’ AI Analyst, HAO is a Neutral.

The overall score reflects a combination of strong valuation, with the stock appearing undervalued, and moderate financial performance, highlighted by revenue growth but hampered by cash flow issues. Technical analysis indicates a lack of strong momentum, contributing to the overall risk profile.

To see Spark’s full report on HAO stock, click here.

More about Haoxi Health Technology Limited Class A

Haoxi Health Technology Limited is a Cayman Islands–incorporated company headquartered in Beijing, China, whose Class A ordinary shares are listed on Nasdaq. The company operates in the health technology sector, although this filing focuses primarily on its capital markets activity rather than operating products or services.

Average Trading Volume: 30,556

Technical Sentiment Signal: Hold

Current Market Cap: $12.78M

For detailed information about HAO stock, go to TipRanks’ Stock Analysis page.